ARMOR

Report Reveals Only 67% of Federal Government Agencies Are Confident in Meeting Zero Trust Executive Order Ahead of 2024 Deadline

Retrieved on: 
Tuesday, August 15, 2023
White House, Federal Government, Public Policy, Government, Security, Technology, Other Technology, Homeland Security, Communication, Federal, DHS, Information Security Automation Program, Trust, Research, Environmental policy of the Joe Biden administration, Public sector, Orchestration, Zero trust security model, ARMOR, DISA, Case management, United States Secretary of Homeland Security, Federation, Gamer, Maturity, SOAR, Medical device, Audit, Swimlane, Automation

Swimlane today announced the release of its report “ Security Automation: A Strategic Imperative for Federal Agencies ” based on research conducted by Dimensional Research.

Key Points: 
  • Swimlane today announced the release of its report “ Security Automation: A Strategic Imperative for Federal Agencies ” based on research conducted by Dimensional Research.
  • The report reveals that federal agencies are prepared to meet the Zero Trust executive order requirements from the Biden Administration with just over a year until the deadline.
  • 64% of federal agencies report it takes longer to fill a security position now than it did two years ago.
  • Federal agencies are turning to low-code security automation to lighten the load of implementing the SOAR component of the executive order.

Cyber Threat Readiness Report Reveals Alarming Misalignment Between Execs and Security Analysts

Retrieved on: 
Tuesday, July 25, 2023
Software, Technology, Internet, Security, Burnout, Workflow, Black hat, Research, Automation, Orchestration, Organization, Head, ARMOR, Maturity, SOAR, Risk management, Medical device, Sales, Online shopping, Framework, Gartner, Swimlane

Swimlane , the low-code security automation company, today announced the release of the “ 2023 Cyber Threat Readiness Report ” based on research conducted by Dimensional Research.

Key Points: 
  • Swimlane , the low-code security automation company, today announced the release of the “ 2023 Cyber Threat Readiness Report ” based on research conducted by Dimensional Research.
  • The report reveals a lack of executive understanding and an ever-widening talent gap that is placing an unsustainable burden on security teams to prevent business-ending breaches.
  • Dimensional Research surveyed 1,005 security professionals and executives at enterprise companies with at least 5,000 employees and $600M in revenue.
  • Over three-quarters (78%) of organizations that handle every alert said they use low-code security automation in their security stack.

Bausch + Lomb Announces the Presentation of New Scientific Data on Products and Pipeline Programs at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, April 26, 2023
Surgery, Medical Devices, Health, Pharmaceutical, Optical, Tradition, Intraocular lens, Aperture, ASCRS, Astigmatism, Pain, Employment, Telecanthus, Incidence, Patient, Outcome, Viral, Steroid, Herpes simplex, NYSE, Chickenpox, Very-small-aperture terminal, Conjunctiva, Cornea, Comparative Effectiveness Research Translation Network, SM, Optic nerve, Cataract, FDA, Emerging technologies, Fungal infection, Refractive surgery, Use, Sclera, Eye, Bausch, History, Thought, American Society of Cataract and Refractive Surgery, Slit lamp, ARMOR, Glaucoma, DED, IOP, Contact lens, Infection, OVD, Inflammation, Vaccinia, Bausch & Lomb, Range, Convention (norm), Visual acuity, Society, Pharmaceutical industry, Telescopic sight, Telescope, Wood drying, Dentistry, Hospital, Retail, Veterinary medicine, Fused quartz, Vaccine, Dietary supplement, Emmetropia, Refraction, IOL

The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.

Key Points: 
  • The posters and presentations include two studies assessing the new StableVisc™ cohesive ophthalmic viscosurgical device, which Bausch + Lomb commercially launched this month.
  • Others include a retrospective chart review on the use of LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38% in refractive surgery and numerous presentations focused on Bausch + Lomb surgical IOL pipeline programs.
  • New data from the Bausch + Lomb Antibiotic Resistance Monitoring in Ocular micRoorganisms (ARMOR) surveillance study will also be presented.
  • “Clinical Evaluation of the Outcomes of Two Preloaded Monofocal IOLs Implanted Bilaterally in Cataract Patients.” Shultz et al.

Bausch + Lomb Announces the Presentation of New Data on Products and Pipeline Programs at the Association for Research in Vision and Ophthalmology Meeting

Retrieved on: 
Thursday, April 20, 2023
Science, Biotechnology, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Hypersensitivity, Meibomian gland, Fetus, Safety, Cataract, Fungus, Dose, Development, Floater, Data analysis, Photophobia, Patient, Risk, Macular edema, Association for Research in Vision and Ophthalmology, Virus, NYSE, Chickenpox, Canker, ARVO, Pregnancy, Conjunctiva, Photopsia, Viral, HPA, Chemosis, Intraocular pressure, Administration, Uveitis, Bacteria, Chalazion, Hypothalamic–pituitary hormone, FDA, Lomb, Hyperglycemia, Perception, Efficacy, Eye, History, Sanfilippo, ARMOR, Triamcinolone, Cover My Eyes (Pain and Heaven), Intraocular lens, Glaucoma, Cornea, Research and development, Nursing, Telecanthus, Vaccinia, Asbell, Bausch & Lomb, Meibomian gland dysfunction, Visual acuity, Pharmaceutical industry, Wood drying, Vaccine, Telescopic sight, Dietary supplement, Ophthalmology, Kalahari Desert

“Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.

Key Points: 
  • “Comparative Evaluation of the Attributes of a New Cohesive Ophthalmic Viscosurgical Device.” Hosten et al.
  • “Early Adoption of Triamcinolone Acetonide Suprachoroidal Injection for Uveitic Macular Edema: A Physician Survey.” Chang et al.
  • “Longitudinal Analysis of In Vitro Antibiotic Resistance Among Ocular Staphylococci Collected in the ARMOR study.” Asbell et al.
  • To report SUSPECTED ADVERSE REACTIONS, contact Bausch + Lomb at 1-800-321-4576 or FDA at 1-800-FDA-1088 or visit www.fda.gov/medwatch .

Bausch + Lomb Will Present New Scientific Data and Analyses During the American Academy of Ophthalmology Annual Meeting

Retrieved on: 
Monday, September 26, 2022
American Academy, Biosimilar, Uveitis, Bausch & Lomb, U.S. Securities and Exchange Commission, Physician, Packer, Macular edema, Research, Triamcinolone, Effectiveness, COVID-19, McCormick Place, GOBI, Treatment, DED, ARMOR, Ranibizumab, Fear, Safety, Gibson, NYSE, Duane syndrome, Lens (anatomy), News, CEO, Instagram, Thomas Leonardi, American Academy of Ophthalmology, Asbell, AAO, Canadian Securities Administrators, Intraocular pressure, MedImmune, Inc. v. Genentech, Inc., Twitter, LinkedIn, Sheppard, Exocrine gland, Facebook, Pharmaceutical industry, Generic drug, Wood drying, Medical device, Patient, United States Department of Agriculture South Building

VAUGHAN, ON, Sept. 26, 2022 /PRNewswire/ -- Bausch + Lomb Corporation (NYSE/TSX: BLCO) ("Bausch + Lomb"), a leading global eye health company dedicated to helping people see better to live better, today announced that seven scientific podium and poster presentations involving its products and pipeline, as well as data from the Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the annual meeting of the American Academy of Ophthalmology (AAO), which will take place in Chicago from Sept. 30 to Oct. 3, 2022.

Key Points: 
  • "Suprachoroidal Triamcinolone Acetonide for Macular Edema Associated with Uveitis: Outcomes by Various Uveitis Subtypes in PEACHTREE."
  • "Suprachoroidal Use of Triamcinolone Acetonide: A Post-Hoc Analysis of PEACHTREE to Evaluate Elevations in Intraocular Pressure."
  • "Efficacy of Suprachoroidal Triamcinolone Acetonide in the Treatment of Uveitic Macular Edema in Patients with Earlier vs. Later Disease."
  • *LUCENTIS is a registered trademark of Genentech Inc.
    /TM aretrademarks of Bausch & Lomb Incorporated or its affiliates.

CORPORATE ARMOR MAKES INC. 5000 LIST for the third year in a row

Retrieved on: 
Monday, August 22, 2022
Newton, Corporation, Pain, Achievement, Commonwealth Associates, Inc., ARMOR, Sophos, Organization, IT service management, Database, Conference, Knowledge, COVID-19, Growth, Industry, Social media, Online shopping, Weapon, Public relations, Inc.

Liz Kinney, Executive at our strategic supplier TD-Synnex, said,"I have enjoyed working with and getting to know the Corporate Armor team the last two and a half years!

Key Points: 
  • Liz Kinney, Executive at our strategic supplier TD-Synnex, said,"I have enjoyed working with and getting to know the Corporate Armor team the last two and a half years!
  • Armed with industry-best cybersecurity offerings, Corporate Armor is on the frontlines in delivering innovative, proactive threat detection and response services.
  • We applaud Corporate Armor on this well-deserved recognition as one of the nation's fastest growing companies."
  • Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States.

COPRORATE ARMOR MAKES INC. 5000 LIST for the third year in a row

Retrieved on: 
Tuesday, August 16, 2022
Newton, Industry, Growth, Database, Commonwealth Associates, Inc., IT service management, Achievement, Knowledge, ARMOR, Pain, Sophos, Armour, Corporation, Social media, COVID-19, Conference, Organization, Online shopping, Weapon, Public relations, Inc.

Corporate Armor makes the Inc. 5000 list for the third year in a row

Key Points: 
  • Corporate Armor makes the Inc. 5000 list for the third year in a row
    We're proud of this achievement as our business grows beyond 8 figures in revenue; double digit growth becomes especially challenging.
  • Armed with industry-best cybersecurity offerings, Corporate Armor is on the frontlines in delivering innovative, proactive threat detection and response services.
  • We applaud Corporate Armor on this well-deserved recognition as one of the nation's fastest growing companies."
  • Its prestigious Inc. 5000 list, produced every year since 1982, analyzes company data to recognize the fastest-growing privately held businesses in the United States.

PharmaNest to Present Eight Digital Pathology and AI Abstracts at the International Liver Congress 2022

Retrieved on: 
Monday, June 20, 2022
Digital pathology, ARMOR, ILC, CEO, Phenotype, University, Therapeutic discovery project, Drug discovery, Bristol Myers Squibb, Artificial intelligence, Marie Cassidy, Partnership, NASH, Inflammation, 2021 Essex County Council election, GLOBE, Medical imaging, Fibrosis

PRINCETON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- PharmaNest, an emerging leader in quantitative Digital Pathology and Artificial Intelligence, announces today that it will be present, alongside with its collaborators, eight presentations at this year's International Liver Congress (ILC) in London, June 22-25, 2022.

Key Points: 
  • PRINCETON, N.J., June 20, 2022 (GLOBE NEWSWIRE) -- PharmaNest, an emerging leader in quantitative Digital Pathology and Artificial Intelligence, announces today that it will be present, alongside with its collaborators, eight presentations at this year's International Liver Congress (ILC) in London, June 22-25, 2022.
  • The first abstract is a retrospective analysis of liver biopsies from the ARMOR Phase 2 trial of aramchol.
  • A second abstract includes results from a prospective analysis of liver biopsies from the FALCON1 Phase 2 trialof pegbelfermin.
  • The specific details of these abstracts are available on PharmaNest website at fibronest.com/science.

Ventura Air Services Achieves Prestigious ARGUS Platinum Rating

Retrieved on: 
Wednesday, June 1, 2022
Aircraft, PRISM, Safety management system, Aviation, CEO, FAA, ARMOR, Organization, Maintenance, Solution, ARGUS, Gold, Platinum, Learjet, International standard, Industry, Overalls, Culture, Bombardier, 2011 New Year Honours (New Zealand), Safety, Airline

FARMINGDALE, N.Y., June 1, 2022 /PRNewswire-PRWeb/ -- Ventura Air Services, a growing private charter aviation company based in Farmingdale, Long Island, NY, has achieved the prestigious ARGUS Platinum Rating. This designation places the company in the upper 25 percent of nearly 600 rated U.S.-based charter operators and further validates a commitment to the highest level of safety held by only an elite group of operators around the globe.

Key Points: 
  • Ventura Air Services, a growing private charter aviation company based in Farmingdale, Long Island, NY, has achieved the prestigious ARGUS Platinum Rating.
  • Receiving the ARGUS Platinum Rating validates that we have taken the right approach," said Nick Tarascio, CEO of Ventura Air Services.
  • In addition to the ARGUS Platinum designation, Ventura Air Services also received the International Standard for Business Aircraft Operations, or IS-BAO Stage 1 certification.
  • Ventura Air Services has been providing charter, sales and aircraft maintenance services for more than 60 years.

InventHelp Inventor Develops Easier Way to Move Lumber on the Shoulder (CNC-768)

Retrieved on: 
Tuesday, May 24, 2022
Multimedia, Bruise, Shoulder, Sale, Pain, Heat, ARMOR, Ninth Street, Fatigue, Safety, Publishing

PITTSBURGH, May 24, 2022 /PRNewswire/ -- "While working as a construction laborer, I was tasked with carrying heavy lumber on my shoulder.

Key Points: 
  • PITTSBURGH, May 24, 2022 /PRNewswire/ -- "While working as a construction laborer, I was tasked with carrying heavy lumber on my shoulder.
  • I thought there could be a better way," said an inventor, from Hendersonville, N.C., "so I invented the BUILDER'S ARMOR.
  • My design allows a worker to move heavy construction materials faster and easier without the pain and bruising."
  • The patent-pending invention provides an easier way to move heavy lumber on one's shoulder.